Where does Illumina Singapore Pte. Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Illumina Singapore Pte. Ltd. ranks #10,060 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Illumina Singapore Pte. Ltd. hold?

Illumina Singapore Pte. Ltd. holds 31 US utility patents granted between 2018 and 2025, spanning 12 technology areas.

What is Illumina Singapore Pte. Ltd.'s Innovation Score?

Illumina Singapore Pte. Ltd. has an Innovation Score of 43.9 out of 100 (top 27% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Illumina Singapore Pte. Ltd.'s patent grant rate increasing or decreasing?

Illumina Singapore Pte. Ltd.'s recent grant velocity is +240% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Illumina Singapore Pte. Ltd.'s patents?

Illumina Singapore Pte. Ltd.'s patents average 14.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Illumina Singapore Pte. Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Illumina Singapore Pte. Ltd.

Q: What technology areas does Illumina Singapore Pte. Ltd. focus on?

Illumina Singapore Pte. Ltd.'s top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 9 patents, ranking #1,126 of 4,144 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

USPTO PatentsView assignee record - 31 granted patents across 12 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Illumina ranks #10,060 of 49,997 tracked US assignees by granted-patent volume, with 31 patents across 12 technology areas.

#10,060
of 49,997 US assignees by volume: Top 27%
by Innovation Score (43.9/100): 14.8
avg claims per patent: +240%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R10060 · Foreign Corporation #10,060 · 31 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 31 grants
UPPER-Q #10,060/49,997
PHOTO-FINISH Hope Medical…
CPC-FOCUS C12N · 12 areas
INNOV-PAR 43.9/100
CLAIMS-RICH 14.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +240% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Hope Medical Enterprises, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Illumina’s 43.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.0 pts (27%) Velocity 10.8 pts (25%) Breadth 12.2 pts (28%) Claim depth 8.9 pts (20%)

Qualcomm Incorporated · highest

85
LGS Innovations · near

44
Zibra · near

44
Abbott Diagnostics… · near

44
Illumina Singapore Pte · this assignee

44
Kaistar Lighting(Xia… · near

44
3D Lighting… · lowest

7

What this shows Illumina's Innovation Score is 43.9/100 (top 27% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Illumina?

Each dot is one of Illumina’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Illumina’s own 14.8 claims/patent is at or below the 18.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Illumina vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Illumina's grants concentrate

Illumina Singapore Pte. Ltd. is a focused PatentsView assignee: 12 CPC subclasses with 29% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2024 (8 grants) versus a trough of 1 in 2018. By volume, Illumina sits between Hope Medical Enterprises, Inc. and Intarcia Therapeutics, Inc..

Illumina's three-year grant acceleration

Illumina Singapore Pte. Ltd. shows 13 grants in 2022–2024 against only 8 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Hope Medical Ente…

31
III Holdings 4

31
Imperial College…

31
Innerworkings

31
Inpro

31
Industrial Scient…

31
Inktec

31
Intarcia Therapeu…

31
Illumina Singapor… ◀

31

What this shows Illumina holds 31 patents at rank #10,062, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Illumina

By rank, the assignees closest to #10,062 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Illumina's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Illumina, neither rank-band nor same-CPC leaders (those blocks stay above). In C12N (Microorganisms OR Enzymes), Illumina ranks #1,126 of 4,144 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (44 here).

Kaistar Lighting(Xiamen) Co., Ltd. 44 Abbott Diagnostics Scarborough, Inc. 44 Zibra, LLC 44 LGS Innovations LLC 44

Illumina's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 27% higher than 73% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Illumina Singapore Pte. Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	3.2%
2019	4	12.9%
2020	2	6.5%
2021	2	6.5%
2022	1	3.2%
2023	4	12.9%
2024	8	25.8%
2025partial year	9	29.0%

Which technologies does Illumina Singapore Pte. Ltd. patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 9

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 8

C12Y - Enzymes 8

B01L - Chemical OR Physical Laboratory Apparatus FOR General USE 8

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 6

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 3

C07K - Peptides 3

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 2

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 2

F04B - Positive-displacement Machines FOR LIQUIDS; Pumps 2

F16K - VALVES; TAPS; COCKS; ACTUATING-FLOATS; Devices FOR Venting OR Aerating 2

F28D - Heat-exchange Apparatus, NOT Provided FOR IN Another Subclass, IN Which THE Heat-exchange Media DO NOT Come Into Direct Contact 1

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Illumina Singapore Pte. Ltd.'s patent record in context - here's where to go next.

Illumina Singapore Pte. Ltd.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 29% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #10,060 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Illumina Singapore Pte. Ltd. against Hope Medical Enterprises, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.